semaglutide patent canada Off-patent in 2026: the next revolution in anti-obesity medications Canada approves first generic version

A sudden improvement in glucose markers, liver enzymes, and lipid profiles has a differential diagnosis

Clinical trials demonstrated average weight loss of 14.9 percent of body weight with the 2.4 mg maintenance dose over 68 weeks

Others think it is a marketing gimmick

Maintenance doses range from 0.5 mg to 2.0 mg weekly (Ozempic) for diabetes and up to 2.4 mg weekly (Wegovy) for weight management

[4] Contact your GP promptly if you experience severe pain in the upper right side of your abdomen, especially if accompanied by fever or yellowing of the skin or eyes

By staying informed and working closely with healthcare providers, patients can successfully manage skin sensitivity and achieve the full benefits of semaglutide